trending Market Intelligence /marketintelligence/en/news-insights/trending/7osJIL29RLBgaZL-BaBQZg2 content esgSubNav
In This List

Multiple myeloma patients respond to GSK drug in early stage study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Multiple myeloma patients respond to GSK drug in early stage study

GlaxoSmithKline plc said GSK2857916 showed positive results in previously treated multiple myeloma patients enrolled in the phase 1/2 DREAMM-1 study.

Multiple myeloma is a bone marrow cancer that affects plasma cells.

The study showed that 60% of the patients responded to GSK2857916 which targets the BCMA protein, responsible for promoting plasma cell survival.

The drug also demonstrated a progression-free survival of 7.9 months, a measure of how long a patient lived before the disease worsening.

More than half of the patients enrolled in the study had undergone five previous lines of therapies. A portion of the patients were previously treated with Johnson & Johnson's Darzalex or daratumumab.

The drug was previously awarded the breakthrough therapy designation from the U.S. Food and Drug Administration and prime designation from the European Medicines Agency.